Kristin M. D’Silva
A5004944795- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Dermatological and COVID-19 studies
- Inflammatory Myopathies and Dermatomyositis
- Systemic Sclerosis and Related Diseases
- Bone health and treatments
- COVID-19 and healthcare impacts
- Inflammasome and immune disorders
- Cancer Immunotherapy and Biomarkers
- Spondyloarthritis Studies and Treatments
- Osteoarthritis Treatment and Mechanisms
- Pulmonary Hypertension Research and Treatments
- Gout, Hyperuricemia, Uric Acid
- Peripheral Neuropathies and Disorders
- Case Reports on Hematomas
- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Renal Diseases and Glomerulopathies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Monoclonal and Polyclonal Antibodies Research
AbbVie (United States)
2023-2025
Rheumazentrum Ruhrgebiet
2024
University of Alberta
2024
VIB-UGent Center for Inflammation Research
2024
Robert Bosch (United States)
2024
Hanyang University Seoul Hospital
2024
Kyorin University
2024
Oregon Health & Science University
2024
Ruhr University Bochum
2024
Ghent University
2024
The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. We performed a randomized, double-blind, placebo-controlled trial involving confirmed severe acute respiratory syndrome 2 (SARS-CoV-2) infection, hyperinflammatory states, and at least two the following signs: fever (body temperature >38°C), pulmonary infiltrates, or need for supplemental oxygen order to maintain an...
To investigate differences in manifestations and outcomes of coronavirus disease 2019 (COVID-19) infection between those with without rheumatic disease.
To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).We analysed the Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD for RA at clinical onset (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 (IL-6i) tumour necrosis factor (TNFi, reference group). The ordinal severity...
Background: Racial inequities for patients with heart failure (HF) have been widely documented. HF who receive cardiology care during a hospital admission better outcomes. It is unknown whether there are differences in to or general medicine service by race. This study examined the relationship between race and service, its effect on 30-day readmission mortality Methods: We performed retrospective cohort from September 2008 November 2017 at single large urban academic referral center of all...
Patients with systemic autoimmune rheumatic diseases (ARDs) continue to be concerned about risks of severe coronavirus disease 2019 (COVID-19) outcomes. This study was undertaken evaluate the outcomes in COVID-19 patients ARDs compared without ARDs.
<h3>Importance</h3> Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact COVID-19 among individuals with IMIDs who receiving TNF remains insufficiently understood. <h3>Objective</h3> To examine association between receipt inhibitor monotherapy and risk COVID-19–associated hospitalization or death compared other commonly immunomodulatory...
Racial/ethnic minorities experience more severe outcomes of coronavirus disease 2019 (COVID-19) in the general US population. This study was undertaken to examine association between race/ethnicity and COVID-19 hospitalization, ventilation status, mortality people with rheumatic disease.US patients were entered into Global Rheumatology Alliance physician registry March 24, 2020 August 26, included. Race/ethnicity defined as White, African American, Latinx, Asian, or other/mixed race. Outcome...
Objective In earlier studies, patients with rheumatic and musculoskeletal disease (RMD) who got infected COVID-19 had a higher risk of mechanical ventilation than comparators. We sought to determine outcomes among RMD 6 months into the pandemic. Methods conducted cohort study at Mass General Brigham in Boston, Massachusetts, matched up five comparators by age, sex diagnosis date (between 30 January 2020 16 July 2020) followed until last encounter or 18 August 2020. were compared using Cox...
BackgroundAs the COVID-19 pandemic continues worldwide, severe outcomes remain a major concern for patients with rheumatic and musculoskeletal diseases. We aimed to investigate temporal trends in diseases over course of pandemic.MethodsUsing large, multicentre, electronic health record network (TriNetX), we did comparative cohort study who were diagnosed (by International Classification Diseases, Tenth Revision code or positive PCR test) during first 90 days (early cohort) compared second...
The 48-week, phase 2 SLEek study (NCT03978520) evaluated the efficacy and safety of upadacitinib (JAK inhibitor) elsubrutinib (BTK alone or in combination (ABBV-599) adults with moderately to severely active systemic lupus erythematosus (SLE).
Patients with immune-mediated diseases treated anti-CD20 monoclonal antibodies may have worse coronavirus disease 2019 (COVID-19) outcomes due to impaired humoral immunity, but differences compared the general population are unknown.We identified patients who received within 1 year prior index date of polymerase chain reaction-confirmed COVID-19 between January 31, 2020, and 2021. General comparators were matched up 5:1 by age, sex, reaction date. Unadjusted multivariable adjusted (for race,...
Increase in protein synthesis contributes to kidney hypertrophy and matrix accumulation diabetes. We have previously shown that high glucose-induced is associated with inactivation of glycogen synthase kinase 3β (GSK3β) renal cells the kidneys diabetic mice. tested whether activation GSK3β by sodium nitroprusside (SNP) mitigates injury Studies kidney-proximal tubular epithelial showed SNP abrogated laminin increment stimulating inhibiting Akt, mTORC1, events mRNA translation regulated mTORC1...
Distinct clinical presentations of interstitial lung disease (ILD) with the myositis-specific antibodies, including anti-synthetase are well-recognized. However, association between ILD and myositis-associated anti-Ro52, is less established. Our objectives were to compare presenting phenotypes patients anti-Ro52 alone versus in combination autoantibodies identify predictors progression or death.We performed a retrospective cohort study 73 adults positive antibody. We report features,...
Upadacitinib improved the signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) versus placebo over 14 weeks in primary analysis SELECT-AXIS 2 nr-axSpA study. Here, we evaluated efficacy safety upadacitinib through 1 year patients with 2.